Pharmacotherapy for coronary microvascular dysfunction

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 1, Issue 1, 2015, Pages 65-71

  Ong, Peter ^a   Athanasiadis, Anastasios ^a   Sechtem, Udo ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Angina pectoris; Coronary microvascular dysfunction; Pharmacotherapy

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILAZAPRIL; DILTIAZEM; ENALAPRIL; ESTROGEN; FLUINDOSTATIN; GLYCERYL TRINITRATE; ISOSORBIDE MONONITRATE; IVABRADINE; METFORMIN; NEBIVOLOL; NICORANDIL; NIFEDIPINE; NISOLDIPINE; NITRIC ACID DERIVATIVE; PLACEBO; PRAVASTATIN; PROPRANOLOL; QUINAPRIL; RAMIPRIL; RANOLAZINE; SIMVASTATIN; TRIMETAZIDINE; UNINDEXED DRUG; VERAPAMIL; CARDIOVASCULAR AGENT;

ANGINA PECTORIS; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; CORONARY MICROVASCULAR DYSFUNCTION; ESTROGEN DEFICIENCY; EXERCISE TEST; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; MICROANGIOPATHY; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; ST SEGMENT DEPRESSION; THORAX PAIN; CORONARY ARTERY BLOOD FLOW; MICROCIRCULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNDROME X; TREATMENT OUTCOME;

CARDIOVASCULAR AGENTS; CORONARY CIRCULATION; HUMANS; MICROCIRCULATION; MICROVASCULAR ANGINA; TREATMENT OUTCOME;

EID: 84931593895     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvu020     Document Type: Review

References (53)

1. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356: 830-840.
2. Crea F, Camici PG, Bairey MerzCN.Coronary microvascular dysfunction: an update. Eur Heart J 2014;35:1101-1111.
3. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van derWall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
4. Kronhaus KD, Lawson WE. Enhanced external counterpulsation is an effective treatment for Syndrome X. Int J Cardiol 2009;135:256-257.
5. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation 2010;121:2317-2325.
6. Kaski JC, Valenzuela Garcia LF. Therapeutic options for the management of patients with cardiac syndrome X. Eur Heart J 2001;22:283-293.
7. Kaski JC, Aldama G, Cosin-Sales J. Cardiac syndrome X. Diagnosis, pathogenesis and management. Am J Cardiovasc Drugs 2004;4:179-194.
8. Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Reichek N, Rogers WJ, Merz CN, Sopko G, Pepine CJ, WISE Investigators. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001;141:735-741.
9. Ong P, Athanasiadis A, Borgulya G, Mahrholdt H, Kaski JC, Sechtem U. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol 2012;59:655-662.
10. Pasceri V, Lanza GA, Buffon A, Montenero AS, Crea F, Maseri A. Role of abnormal pain sensitivity and behavioral factors in determining chest pain in syndrome X. J Am Coll Cardiol 1998;31:62-66.
11. Lanza GA, Giordano A, Pristipino C, Calcagni ML, Meduri G, Trani C, Franceschini R, Crea F, Troncone L, Maseri A. Abnormal cardiac adrenergic nerve function in patients with syndrome X detected by [123I]metaiodobenzylguanidine myocardial scintigraphy. Circulation 1997;96:821-826.
12. Granger DN, Rodrigues SF, Yildirim A, Senchenkova EY. Microvascular responses to cardiovascular risk factors. Microcirculation 2010;17:192-205.
13. Vermeltfoort IA, Raijmakers PG, Riphagen II, Odekerken DA, Kuijper AF, Zwijnenburg A, Teule GJ. Definitions and incidence of cardiac syndrome X: review and analysis of clinical data. Clin Res Cardiol 2010;99:475-481.
14. Day LJ, Sowton E. Clinical features and follow-up of patients with angina and normal coronary arteries. Lancet 1976;2:334-337.
15. Isner JM, Fisher GP, Del Negro AA, Borer JS. Right ventricular infarction with hemodynamic decompensation due to transient loss of active atrial augmentation: successful treatment with atrial pacing. Am Heart J 1981;102:792-794.
16. Matsumoto T, Takahashi M, Omura T, Takaoka A, Liu Q, Nakae I, Kinoshita M. Heterogeneity in the vasorelaxing effect of nicorandil on dog epicardial coronary arteries: comparison with other NO donors. J Cardiovasc Pharmacol 1997;29:772-779.
17. Russo G, Di Franco A, Lamendola P, Tarzia P, Nerla R, Stazi A, Villano A, Sestito A, Lanza GA, Crea F. Lack of effect of nitrates on exercise stress test results in patients with microvascular angina. Cardiovasc Drugs Ther 2013;27:229-334.
18. Romeo F, Gaspardone A, Ciavolella M, Gioffre P, Reale A. Verapamil versus acebutolol for syndrome X. Am J Cardiol 1988;62:312-313.
19. Ferrini D, Bugiardini R, Galvani M, Gridelli C, Tollemeto D, Puddu P, Lenzi S. [Opposing effects of propranolol and diltiazem on the angina threshold during an exercise test in patients with syndrome X]. G Ital Cardiol 1986;16:224-231.
20. Leonardo F, Fragasso G, Rossetti E, Dabrowski P, Pagnotta P, Rosano GM, Chierchia SL. Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance. Cardiologia 1999;44: 1065-1069.
21. Erdamar H, Sen N, Tavil Y, Yazici HU, Turfan M, Poyraz F, Topal S, Okuyan H, Cemri M, Cengel A. The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. Coron Artery Dis 2009;20: 238-244.
22. Leonardo F, Fragasso G, Rosano GM, Pagnotta P, Chierchia SL. Effect of atenolol on QT interval and dispersion in patients with syndrome X. Am J Cardiol 1997; 80:789-790.
23. Robertson RM, Wood AJ, Vaughn WK, Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. Circulation 1982;65:281-285.
24. Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 1994;23:652-657.
25. Nalbantgil I, Onder R, Altintig A, Nalbantgil S, Kiliccioglu B, Boydak B, Yilmaz H. Therapeutic benefits of cilazapril in patients with syndrome X. Cardiology 1998;89: 130-133.
26. Ozcelik F, Altun A, Ozbay G. Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X. Clin Cardiol 1999;22:361-365.
27. Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzymeAreductase in cardiac Syndrome X: role of superoxide dismutase activity. Circulation 2004;109:53-58.
28. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002;90:974-982.
29. PaulyDF, JohnsonBD, Anderson RD, Handberg EM, Smith KM, Cooper-DeHoffRM, Sopko G, Sharaf BM, Kelsey SF, Merz CN, Pepine CJ. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Womens Ischemia Syndrome Evaluation (WISE). Am Heart J 2011;162:678-684.
30. Cannon RO III, Watson RM, Rosing DR, Epstein SE. Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve. Am J Cardiol 1985;56:242-246.
31. Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol 1999; 84:854-856.
32. Sorop O, Bakker EN, Pistea A, Spaan JA, VanBavel E. Calcium channel blockade prevents pressure-dependent inward remodeling in isolated subendocardial resistance vessels. Am J Physiol Heart Circ Physiol 2006;291:H1236-H1245.
33. Kayikcioglu M, Payzin S, Yavuzgil O, Kultursay H, Can LH, Soydan I. Benefits of statin treatment in cardiac syndrome-X. Eur Heart J 2003;24:1999-2005.
34. Fabian E, Varga A, Picano E, Vajo Z, Ronaszeki A, Csanady M. Effect of simvastatin on endothelial function in cardiac syndromeX patients. Am J Cardiol 2004;94:652-655.
35. Zhang X, Li Q, Zhao J, Li X, Sun X, Yang H, Wu Z, Yang J. Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X. Coron Artery Dis 2014;25:40-44.
36. Mehta PK, Goykhman P, Thomson LE, Shufelt C, Wei J, Yang Y, Gill E, Minissian M, Shaw LJ, Slomka PJ, Slivka M, Berman DS, Bairey Merz CN. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging 2011;4:514-522.
37. Villano A, Di Franco A, Nerla R, Sestito A, Tarzia P, Lamendola P, Di Monaco A, Sarullo FM, Lanza GA, Crea F. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol 2013;112:8-13.
38. Tagliamonte E, Rigo F, Cirillo T, Astarita C, Quaranta G, Marinelli U, Caruso A, Romano C, Capuano N. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease. Echocardiography 2014.
39. Jadhav S, FerrellW, Greer IA, Petrie JR, Cobbe SM, Sattar N. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2006;48:956-963.
40. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006;55:496-505.
41. Nalbantgil S, Altintig A, Yilmaz H, Nalbantgil II,O nder R. The effect of trimetazidine in the treatment of microvascular angina. Int J Angiol 1999;8:40-43.
42. Yamabe H, Namura H, Yano T, Fujita H, Kim S, Iwahashi M, Maeda K, Yokoyama M. Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms. Cardiovasc Drugs Ther 1995;9:755-761.
43. Chen JW, Lee WL, Hsu NW, Lin SJ, Ting CT, Wang SP, Chang MS. Effects of shortterm treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. Am J Cardiol 1997;80:32-38.
44. Rosano GM, Collins P, Kaski JC, Lindsay DC, Sarrel PM, Poole-Wilson PA. Syndrome X in women is associated with oestrogen deficiency. Eur Heart J 1995;16:610-614.
45. Kaski JC. Overview of gender aspects of cardiac syndrome X. Cardiovasc Res 2002;53: 620-626.
46. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89: 2545-2551.
47. Cannon RO, Quyyumi AA, Mincemoyer R, Stine AM, Gracely RH, Smith WB, Geraci MF, Black BC, Uhde TW, Waclawiw MA, Maher K, Stanley B. Benjamin Imipramine in Patients with Chest Pain Despite Normal Coronary Angiograms.NEngl JMed 1994;330:1411-1417.
48. Cox ID, Hann CM, Kaski JC. Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J 1998;19:250-254.
49. Yoshio H, Shimizu M, Kita Y, Ino H, Kaku B, Taki J, Takeda R. Effects of short-term aminophylline administration on cardiac functional reserve in patients with syndrome X. J Am Coll Cardiol 1995;25:1547-1551.
50. Elliott PM, Krzyzowska-Dickinson K, Calvino R, Hann C, Kaski JC. Effect of oral aminophylline in patients with angina and normal coronary arteriograms (cardiac syndrome X). Heart 1997;77:523-526.
51. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, Lennon R, Rihal C, Lerman LO, Lerman A. Long-termadministration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010;122:958-966.
52. Fukumoto Y, Mohri M, Inokuchi K, Ito A, Hirakawa Y, Masumoto A, Hirooka Y, Takeshita A, Shimokawa H. Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol 2007;49:117-121.
53. Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, Dorbala S, Blankstein R, Rimoldi O, Camici PG, Di Carli MF. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation 2014;129:2518-2527.